Endoscopic ultrasonography (EUS) is an essential endoscopic tool within the diagnostic and therapeutic armamentarium of gastrointestinal and hepatic diseases. EUS-guided tissue acquisition will develop towards facilitating personalized treatment by obtaining large representative tissue specimens for elaborate immunohistochemical and biomolecular typing of the tumor. Intratumoral or intravascular delivery of drugs potentially offers many advantages over systemic injection. Intratumoral application of radiofrequency ablation and photodynamic therapy show promise but need to be explored further.
INTRODUCTION
O VER THE YEARS, endoscopic ultrasonography (EUS) has transformed from a solely diagnostic modality into a versatile interventional tool that has shown to be extremely valuable in a variety of diagnostic and therapeutic scenarios. Undoubtedly, acquisition of tissues by means of fine-needle aspiration (FNA) or fine-needle biopsy (FNB) is and will remain the mainstay for EUS for many years to come. It will guide personalized cancer treatment by enabling tissue sampling from the primary tumor or its metastases to facilitate and optimize the choice of targeted immune-and chemotherapeutic agents. Moreover, intratumoral delivery of drugs and devices has been proven feasible and safe and may open up a new array of possibilities of which we have only scratched the surface. EUS-guided interventional procedures to drain infected necrosis of patients with acute pancreatitis into the digestive tract are nowadays carried out routinely in clinical practice. Ongoing development of devices including lumen-apposing stents are advancing its indications both in terms of feasibility and safety as well as the span of indications beyond draining fluid collections.
EUS-GUIDED TISSUE ACQUISITION
T HERE IS NO doubt that tissue acquisition will remain the mainstay of interventional EUS for many years to come. In particular, the advent of neoadjuvant therapy, improving patient survival in more advanced stages of various upper gastrointestinal (GI) cancers, has pushed the clinical utility of EUS-guided tissue acquisition. Its focus, however, will shift from solely making a tissue diagnosis of cancer towards acquiring a detailed analysis of the tumor's signature or response to various drug compounds to guide personalized treatment with targeted antitumor regimens throughout a patient's disease course. This also implies that as the disease progresses, a repeat EUS-guided biopsy may be required in order to reassess the tumor's signature and shift gears with respect to drug therapy.
For example, Roife et al. developed a unique ex vivo live tissue sensitivity assay in which precision-cut and uniform small tissue slices derived from pancreatic ductal adenocarcinoma of patient-derived xenografts were arrayed in a 96-well plate and screened against clinically relevant regimens within 3-5 days.
1 Importantly, the ex vivo tissue slices remained viable for at least 5 days, and the tumor parenchyma, including stroma, vascular structures, and signaling pathways, were all retained. Sensitivities of the ex vivo tissue slices to gemcitabine and irinotecan were consistent with the clinical responses and outcomes of the patients from whom the tumor grafts were derived. Retrospective analysis showed that patients who received live tissue sensitivity assay-sensitive regimens had longer progression-free survival than patients who received live tissue sensitivity assay-resistant regimens. Multiple groups recently showed that this approach is highly feasible and efficient for the initiation and characterization of lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates. 2, 3 This applied to both transbronchial needle aspirates from primary tumor as well as from metastatic lymph nodes, and resulting xenograft tumors were similar to the matched primary and secondary tumors by both histology and chemosensitivity. Leong et al. showed that endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) aspirates yielded large numbers of viable tumor cells sufficient to inject (between 18 750 and 1 487 000 cells per flank), and to yield microgram quantities of high-quality DNA. 4 The engraftment rate was successful in 10 out of 12 patients (83%) with a mean latency of 104 days (range 63-188). All but one maintained a typical tumor phenotype and mutations that closely matched the original sample. The authors concluded that EBUS-TBNA has the potential to be a powerful tool in the development of new targeting strategies for lung cancer patients by providing large numbers of viable tumor cells suitable for both xenografting and complex genomic analysis.
EUS-GUIDED INTRATUMORAL DRUG DELIVERY, RADIOFREQUENCY ABLATION, AND BRACHYTHERAPY
E US -guided injection of alcohol into the celiac plexus in patients with intractable pain as a result of pancreatic cancer or chronic pancreatitis has already been practiced since 1996. 5 Although its efficacy is reported to be highly variable, it has shown to be a relatively easy and feasible procedure with very few side-effects. The EUS-guided injection of alcohol in pancreatic cyst or for neuroendocrine pancreatic tumors was the next area to be explored. Although shown to be feasible, concerns remain about its safety and radicality; that is, whether all neoplastic tissue gets destroyed, and whether preceding alcohol injections hinder early detection of residual tumor or recurrence. 6, 7 In a recent paper, Paik et al. reported on the treatment of eight patients with small borderline malignant pancreatic neoplasms and comorbidities who refused surgery (nonfunctioning neuroendocrine tumor [NET] n = 2, insulinoma n = 3, gastrinoma n = 1, solid pseudopapillary neoplasm n = 2) with a mean diameter of 15 mm. 8 Median volume of injected ethanol was 2.8 mL. There was one case that developed severe post-procedural acute pancreatitis. During a median follow up of only 16.5 months, six patients were designated as being treated successfully. Two patients had a persistent or recurrent tumor for which one patient underwent surgical resection whereas the other patient was retreated with alcohol injection. In a quest not to be solely dependent on the direct toxic effect of alcohol, it was recently shown that combination injections with paclitaxel are also feasible, potentially enhancing the treatment effect. 7, 9 EUS-guided fine needle injection (EUS-FNI) for intratumoral pancreatic cancer therapy involves antitumoral agents and immunotherapy. Over the past years, a number of studies have been published using different agents injected by EUS-FNI including lymphocyte cultures (Cytoimplant), 10 viral vectors (TNFerade), [11] [12] [13] oncolytic viruses (ONYX-015), 14 and dendritic cells. [15] [16] [17] Although clinical outcomes with regard to disease-free survival did not show any benefit to date, all studies showed that injections of these drug compounds were feasible with none to minimal side-effects. One of the more recent studies on this topic was published by Karaca et al. to determine the feasibility of EUS-guided injection of drugloaded microbeads into swine pancreas. 18 These beads are designed for time-released delivery of the chemotherapeutic agent irinotecan into focal, hypervascularized, hepatic tumors. After injection of beads with/without irinotecan with a 19-gauge needle, in 10 of 12 animals an intrapancreatic, hyperechoic focus with an average diameter of 2.2 cm was visible by EUS, and a hypodense area in the tail of the pancreas was visible by contrast computed tomography (CT). In two animals (one with irinotecan and one without) no beads were seen on CT. In 10 of 12 animals, a depot of beads was located in the tail of the pancreas on gross inspection and histology. Drug depot with only localized pancreatic tissue reactions was seen on histopathological review.
Radiofrequency ablation (RFA) is an accepted method of tissue destruction for solid organ tumors that has been used in hepatocellular carcinoma, for example, for years with an excellent outcome and safety profile. EUS-guided RFA was tested in the pancreas of pigs. 19 Complications were relatively mild and pathology showed a well-demarcated acute coagulation zone of 8 to 10 mm in all specimens. In yet another animal study, 18 mediastinal lymph nodes were targeted using EUS-guided radiofrequency ablation. 20 Although the length and diameter of necrosis did not match the size of the treated lymph nodes, the procedure was well feasible and tolerated without side-effects. In a multicenter, pilot safety feasibility study, EUS-guided radiofrequency ablation was applied in eight patients with a tumor in the head of the pancreas (cystic neoplasm n = 6, pancreatic NET n = 2) with a mean diameter of 36.5 mm. 21 No major complications were observed. Post-procedure imaging at 3-6 months showed complete resolution of pancreatic cysts in two of six cases and a 48.4% reduction in lesion size in three patients. As a variation to the theme of controlled local tissue destruction, Arcidiacono et al. investigated the feasibility and safety of EUS-guided cryothermal ablation in 22 patients with advanced pancreatic tumors. 22 The treatment was successfully applied in approximately three-quarters of the patients. In six patients, the treatment could not be carried out because of the inability to advance the cryothermal probe through the gastrointestinal wall and/or tumor. None of the patients developed clinical signs of pancreatitis. Regarding clinical efficacy including local tumor control and progression-free survival, no definite conclusions could be drawn. Presently, a multicenter French study is underway testing the applicability, safety and outcome of EUS-guided RFA of NET.
EUS-guided photodynamic therapy is another technique aiming at local tumor destruction and in which tumor damage is induced by photochemical tissue necrosis after giving i.v. photodynamic agent. Animal case series studies show that the technique is feasible and can be carried out safely with minimal side-effects. [23] [24] [25] EUS-guided photodynamic therapy in four patients with locally advanced pancreaticobiliary malignancies showed technical feasibility in all patients without occurrence of treatment-related complications (Fig. 1) . 26 Median volume of necrosis incurred by EUSguided photodynamic therapy was 4.0 cm (range 0.7-11.3). Disease remained stable in all four patients during a median follow up of 5 months (range 3-7).
Evidently, EUS-guided FNI of drugs as well as EUSguided tumor ablative techniques are still experimental treatments used by only a few pioneers. The search should go on to identify drug compounds that offer additional Digestive
benefit when delivered locally and to gain more knowledge in order to fine-tune the local effects of physical ablative therapies to maximize treatment effect while minimizing the risk of complications. Until then, these therapies should be restricted to patients who refuse or are not eligible for surgery and offered only in a study setting.
EUS AND VASCULAR INTERVENTIONS
S EVERAL ANIMAL PORCINE studies have been done in which angiography of the major abdominal vessels, 27 portal vein angiography and pressure monitoring [28] [29] [30] [31] [32] have been tested. For example, Giday et al. assessed the feasibility of EUS-guided portal vein angiography with a 25-gauge FNA needle by using carbon dioxide (CO 2 ) as a contrast agent in a porcine model. 32 As compared to injection of ionic iodinated contrast, injection of CO 2 through a 25-gauge needle was simple and easy, producing prolonged opacification of the entire portal system with an excellent visualization score. Post-mortem examination revealed no active bleeding and no damage to the liver, other intra-abdominal organs, or blood vessels.
Besides portal vein angiography, direct EUS-guided access into the portal vein opens up an array of possibilities and new indications for EUS, including endoscopic ultrasonography-guided portal injection chemotherapy. Faigel et al. hypothesized that endoscopic ultrasonography-guided portal injection chemotherapy using irinotecan-loaded microbeads may achieve increased intrahepatic concentrations for the treatment of diffuse liver metastases, while decreasing systemic exposure. 33 To test this assumption they carried out this procedure in eight pigs. No adverse events occurred. Compared with systemic administration, endoscopic ultrasonography-guided portal injection chemotherapy resulted in almost twice the hepatic concentration of irinotecan and half the systemic concentrations in plasma, bone marrow and skeletal muscle. Liver histology showed the beads within small portal venules. The authors concluded that endoscopic ultrasonography-guided portal injection chemotherapy using irinotecan-loaded microbeads enhances hepatic exposure to irinotecan, while decreasing systemic concentrations and that the microbeads seem to act as a reservoir resulting in prolonged hepatic drug exposure. The same authors conducted a follow-up study in 24 anesthetized pigs comparing direct injection of chemotherapy into the portal vein with systemic injection for three different chemotherapeutic agents, namely, irinotecan (microbeads), doxorubicin (microbeads), or albumin-bound paclitaxel nanoparticles. 34 EUS-guided access and injection was successful in all animals. Again, as in their former experiment, endoscopic ultrasonography-guided portal injection chemotherapy with irinotecan-loaded microbeads showed nearly double the hepatic concentration compared with systemic injection and almost half the systemic levels. Endoscopic ultrasonography-guided portal injection chemotherapy with doxorubicin-loaded microbeads showed a five-fold increase in hepatic levels and a 30-fold decrease in cardiac levels compared with systemic administration. Last, endoscopic ultrasonography-guided portal injection chemotherapy with albumin-bound paclitaxel nanoparticles increased hepatic concentrations by 60% and decreased systemic levels by 24% to 32%. Endoscopic ultrasonography-guided portal injection chemotherapy may hold significant promise as a novel technique of chemotherapeutic drug delivery in the liver to maximize the dosage and exposure while decreasing systemic drug exposure and thereby the likely occurrence of short-and long-term sideeffects.
Another opportunity offered by EUS-guided portal vein catheterization is direct pressure measurement which potentially opens op an array of possibilities for diagnosis and monitoring of portal hypertension. Lai et al. tested the feasibility and safety of EUS-guided portal vein catheterization by using a 22-gauge needle in seven normal pigs and 14 pigs with portal hypertension (7/14 anticoagulated). 28 Catheterization was not possible by EUS in three animals. One anticoagulated animal had a small amount of periduodenal bleeding as a result of EUS catheterization. There was a close correlation under all conditions between the mean portal vein pressures obtained by EUS and transhepatic catheterization (r = 0.91). The authors concluded that EUSguided portal vein catheterization appears to be feasible in an animal model and provides accurate pressure measurements.
Giday et al. also evaluated the feasibility and the safety of EUS-guided PV catheterization and pressure measurements in five pigs. 30 The portal vein was punctured under EUS guidance by using a 19-gauge FNA needle through which a 0.035-inch guidewire was advanced into the portal vein. After the needle was withdrawn, a 5.5-Fr endoscopic retrograde cholangiopancreatography (ERCP) catheter was advanced over the guidewire into the portal vein and then connected to a pressure monitor. Continuous measurements were obtained for an hour. There were no changes in vital signs and hemodynamic parameters during portal vein catheterizations, angiography, pressure measurements, and catheter removal. Survival experiments in two pigs did not demonstrate any change in animal condition, behavior, or eating habits after the procedure. A necropsy in all animals revealed no active bleeding, and no damage to the liver, other intra-abdominal organs, or blood vessels.
EUS TO CONNECT LUMINAL SPACES
E NDOSCOPIC APPOSITION AND connection of luminal structures within the gastrointestinal tract has gained a lot of attention and has been the subject of many studies as these minimally invasive procedures provide ample opportunity to simplify existing medical treatments that often involve invasive surgical procedures with substantial complication rates, prolonged hospital admission and ensuing high costs.
The first endoscopic cyst-gastrostomy and cyst-duodenostomy procedures were carried out by Sahel et 35, 36 At that time, the procedures were carried out 'blindly'. The bulging cyst was identified endoscopically after which the collection was punctured with a precut needle using electrocautery. Soon after its introduction, radial EUS was used to determine the most optimal site for access and avoid accidental puncture of interposing vessels between the stomach wall and the cyst. 37, 38 A significant advancement in the development of interventional EUS was achieved by Grimm et al. in 1992. 39 They drained a pseudocyst by carrying out the puncture and the guidewire placement under EUS guidance using a linear echoendoscope. As a result of a restriction of the small working channel of only 2.0 mm, the linear echoendoscope had to be exchanged for a regular side-viewing endoscope in order complete the procedure and place plastic stents. Thereafter, many researchers were involved in further developing and refining of the technical procedure of EUS-guided drainage of fluid collections. [40] [41] [42] With the introduction of the therapeutic linear echoendoscope with a large working channel, it became possible to complete the procedure, including placement of multiple large-bore stents, without the need for changing endoscopes. In a prospective randomized trial, Varadarajulu et al. randomized patients with symptomatic pancreatic pseudocysts that measured >4 cm in size between pseudocyst drainage by EUS or by standard endoscopy. 43 All the patients randomized to an EUS underwent successful drainage, in contrast to only 33% of patients randomized to endoscopy. Patients that failed standard endoscopic treatment were successfully treated with EUS-guided drainage except for one in whom severe bleeding occurred which resulted in death. Nowadays, EUS-guided drainage of pseudocyst or infected walled-off necrosis is the preferred treatment in most centers. Only cases not amenable for endoscopic treatment because of a location too distant from the stomach or duodenum wall or failure of endoscopic treatment are referred for surgical of percutaneous intervention. [43] [44] [45] [46] [47] [48] [49] [50] A small retrospective case-controlled study in which surgical cyst-gastrostomy was compared with EUS-guided endoscopic drainage showed comparable success, re-intervention and complication rates. 51 However, because of a shorter mean hospital stay, the endoscopic treatment was more cost-effective.
After gaining initial experience with draining pancreatic fluid collections, the indication for EUS-guided drainage has expanded to drainage of pelvic abscesses, [52] [53] [54] and the biliary system, including EUS-guided hepaticogastrostomy, [55] [56] [57] [58] [59] [60] [61] [62] [63] EUS-guided choledochoduodenostomy, [64] [65] [66] [67] EUS-guided cholecystostomy 68, 69 and, last, EUS-guided pancreaticogastrostomy. [70] [71] [72] [73] Many of these developments have been greatly facilitated by the introduction of fully covered expandable lumen-apposing stents, minimizing the risk of post-procedural leakage.
A novel indication for EUS-guided treatment is the creation of a gastroenterostomy. Traditionally, surgical gastroenterostomy is the treatment of choice in the palliation of malignant gastric outlet obstruction whereas endoscopic placement of luminal self-expandable metallic stents (SEMS) is an alternative treatment for patients with a shorter life expectancy. Although luminal SEMS have been shown to be safe, randomized trials reveal mixed results pertaining to treatment efficacy and long-term outcome. It seems that surgical gastroenterostomy provides longer patency, but at the costs of surgery-related morbidity including delayed gastric emptying, longer hospital stay, increased cost, and a possible delay in cancer treatment. No wonder that attempts were made to create an EUS-guided durable gastroenterostomy in order to have the best of both worlds: prolonged patency achieved by means of a minimally invasive endoscopic procedure.
Binmoeller and Shah evaluated the technical feasibility and outcomes of a new method of EUS-guided gastroenterostomy using novel tools designed for transluminal therapy in five pigs (Fig. 2) . 74 Through a standard 19-G FNA needle, an anchor guidewire was inserted to appose the small-bowel and stomach walls after which an access device created a 3.5-mm fistula opening for insertion of the stent delivery catheter. The procedure was technically successful in all animals without complications. In one acute animal, necropsy showed good stent position and no tissue injury. In four survival animals, the stents remained fully patent and all animals showed normal eating behavior without signs of infection. Stents were easily removed without tissue trauma at 4.5 weeks (n = 3) or 5.5 weeks (n = 1). After stent removal, the tracts appeared mature and were easily intubated with the gastroscope. Necropsy and histopathology showed complete fusion of the stomach and small-bowel wall layers at the site of the gastroenterostomy.
Itoi et al. evaluated a novel EUS-guided gastrojejunostomy technique using a new enteric balloon and lumen-apposing Digestive Endoscopy 2017; 29: 503-511
Interventional EUS: Where are we headed? 507 metal stent in five pigs. 75 All stents, with one exception, were successfully deployed without any adverse events. The mean time to stent placement was 44.2 min (range 28-64 min). All animals showed normal eating behavior without signs of infection for 1 month after the procedure. Endoscopic imaging of the stomach site showed the stent to be patent and stable, without dislodgment, in all of the pigs.
Tyberg et al. 76 and Itoi et al. 75 were two of the first to report the successful human application of EUS-guided gastrojejunostomy. Only very recently, the results of a prospective multicenter registry pertaining EUS-guided gastrojejunostomy using a fully covered lumen-apposing stent were published that included 26 patients, in whom technical success was achieved in 92 % and clinical success in 85 % of cases. 77 Of the four patients in whom clinical success was not achieved, two had persistent nausea and vomiting despite a patent EUS-gastrojejunostomy and required enteral feeding for nutrition, one died before the start of an oral diet, and one underwent surgery for suspected perforation. Adverse events, including peritonitis, bleeding, and surgery, occurred in three patients (11.5 %) . CONCLUSION E NDOSCOPIC ULTRASONOGRAPHY IS an essential endoscopic tool within the diagnostic and therapeutic armamentarium of gastrointestinal and hepatic diseases. Exciting frontiers and novel indications will further challenge and expand its applicability. EUS-guided tissue acquisition will facilitate personalized treatment by obtaining large representative tissue specimens for elaborate immunohistochemical and biomolecular typing of the tumor. Intratumoral or intravascular delivery of drugs has been proven feasible in animals and potentially offers many advantages over systemic injection. Intratumoral application of RFA and photodynamic therapy shows promise but needs to be explored further. Possibilities to apposition and connect luminal structures within the gastrointestinal tract using fully covered expandable lumen-apposing stents will expand its indication far beyond the drainage of (infected) fluid collections of which EUS-guided gastrojejunostomy is a particularly exciting development which could have a significant impact on the management of gastric outlet obstruction.
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